MedTrace Logo

Study To Estimate The Relative Bioavailability of Ertugliflozin (PF-04971729, MK-8835) in Healthy Adult Participants (MK-8835-039)

NCT01114568 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-03-17

No results posted yet for this study

Summary

The purpose of this study is to examine the rate and extent of absorption of three oral formulations of ertugliflozin (PF 04971729, MK-8835) administered in lean to obese healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

Ertugliflozin 10 mg tablet

A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.

DRUG

Ertugliflozin OC Fast

Formulation B) Ertugliflozin 10 mg OC Fast

DRUG

Ertugliflozin OC Slow

Formulation C) Ertugliflozin 10 mg OC Slow

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-06-30
Completion
2010-06-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01114568 on ClinicalTrials.gov